drugset

drugset / Trial / NCT00537901

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study

NCT00537901 ↗

Completed 100 enrolled King Faisal Specialist Hospital & Research Center

Non-randomizedSingle-groupOpen-labelTreatment

Summary

First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum

Timeline

Start: 2007-10
Primary completion: 2013-10
Completion: 2013-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	—	—

Indications